Medullary allotransplant in acute myeloblastic leukemia in a child

Abstract Although acute myeloblastic leukemia (AML) is more resistant to chemotherapy than acute lymphoblastic leukemia (ALL), significant progresses have been achieved over the last 20 years with an improvement in the long-term survival up to 50-60%. This may be attributed to the intensification of...

Descripción completa

Detalles Bibliográficos
Autores principales: Buga Corbu, V, Glűck, R, Arion, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2014
Materias:
Young Researchers Area
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233458/
https://www.ncbi.nlm.nih.gov/pubmed/25408774
_version_ 1782344719753281536
author Buga Corbu, V
Glűck, R
Arion, C
author_facet Buga Corbu, V
Glűck, R
Arion, C
author_sort Buga Corbu, V
collection PubMed
description Abstract Although acute myeloblastic leukemia (AML) is more resistant to chemotherapy than acute lymphoblastic leukemia (ALL), significant progresses have been achieved over the last 20 years with an improvement in the long-term survival up to 50-60%. This may be attributed to the intensification of chemotherapy, including the increased use of stem-cell transplantation (HSCT) in well-defined subgroups. Allo-HSCT represents an extremely effective alternative in pediatric AML treatment panel, but its efficiency is limited both by the toxic effects and by the difficulty of finding a matched HLA donor.
format Online
Article
Text
id pubmed-4233458
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Carol Davila University Press
record_format MEDLINE/PubMed
spelling pubmed-42334582014-11-18 Medullary allotransplant in acute myeloblastic leukemia in a child Buga Corbu, V Glűck, R Arion, C J Med Life Young Researchers Area Abstract Although acute myeloblastic leukemia (AML) is more resistant to chemotherapy than acute lymphoblastic leukemia (ALL), significant progresses have been achieved over the last 20 years with an improvement in the long-term survival up to 50-60%. This may be attributed to the intensification of chemotherapy, including the increased use of stem-cell transplantation (HSCT) in well-defined subgroups. Allo-HSCT represents an extremely effective alternative in pediatric AML treatment panel, but its efficiency is limited both by the toxic effects and by the difficulty of finding a matched HLA donor. Carol Davila University Press 2014-09-15 2014-09-25 /pmc/articles/PMC4233458/ /pubmed/25408774 Text en ©Carol Davila University Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Young Researchers Area
Buga Corbu, V
Glűck, R
Arion, C
Medullary allotransplant in acute myeloblastic leukemia in a child
title Medullary allotransplant in acute myeloblastic leukemia in a child
title_full Medullary allotransplant in acute myeloblastic leukemia in a child
title_fullStr Medullary allotransplant in acute myeloblastic leukemia in a child
title_full_unstemmed Medullary allotransplant in acute myeloblastic leukemia in a child
title_short Medullary allotransplant in acute myeloblastic leukemia in a child
title_sort medullary allotransplant in acute myeloblastic leukemia in a child
topic Young Researchers Area
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4233458/
https://www.ncbi.nlm.nih.gov/pubmed/25408774
work_keys_str_mv AT bugacorbuv medullaryallotransplantinacutemyeloblasticleukemiainachild
AT gluckr medullaryallotransplantinacutemyeloblasticleukemiainachild
AT arionc medullaryallotransplantinacutemyeloblasticleukemiainachild

Ejemplares similares